|Bid||3.6700 x 4000|
|Ask||0.0000 x 36100|
|Day's Range||3.5100 - 3.7400|
|52 Week Range||3.4000 - 10.3200|
|Beta (3Y Monthly)||2.98|
|PE Ratio (TTM)||17.08|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Noah Hamman, CEO of AdvisorShares, tells Yahoo Finance's Alexis Christoforous and Brian Sozzi why he's still bullish on cannabis stocks.
HEXO plans to report its Q4 earnings before the market opens on October 24. October has been tough for Hexo, with its stock falling 31.2% as of October 18.
We discuss Aurora Cannabis's price target cut as well as recent options trades—and what ACB investors can expect from the stock this week.
The cannabis industry’s woes refuse to die down. Cash-rich companies Aurora Cannabis, Canopy Growth, Aphria, and Cronos Group are also suffering.
We are once again optimistic about the IC business of Boston Scientific (BSX), which is likely to have aided the company to retain impressive global growth in Q3.
Cannabis Countdown: Top 10 Marijuana Stock News Stories of the Week Welcome to the Cannabis Countdown . In this week’s rendition, we’ll recap and countdown the top 10 marijuana stock news stories for ...
CALGARY , Oct. 21, 2019 /CNW/ - High Tide Inc. ("High Tide" or the "Company") (HITI.CN) (HITIF) (2LY.F), an Alberta -based, retail-focused cannabis corporation enhanced by the manufacturing and wholesale distribution of smoking accessories and cannabis lifestyle products, today announced over $797,000 in systemwide gross sales from the 26 branded Canna Cabana and KushBar retail cannabis stores from Thursday, October 17th – the first anniversary of the legalization of recreational cannabis for adult use across Canada (the "Anniversary of Legalization") – through Saturday, October 19, 2019 . Similar to its yearly reporting of retail sales related to April 20th , also known as '4/20' in cannabis culture, the Company expects to announce the results associated with the annual Anniversary of Legalization going forward.
Canadian cannabis companies should be celebrating the first anniversary of legalized weed on Thursday, but the party atmosphere has been tainted by a sharp three-month selloff that has seen many companies surrender half their value or more.
On the markets front, Cronos Group Inc (NASDAQ: CRON) posted gains of up to 40% on Wednesday’s after-hours session. Aphria Inc (TSX: APHA) (NYSE: APHA) went on a rally after reporting net first-quarter revenue of CA$126.1 million ($95.3 million), up 849% year-over-year, on revenue for adult-use cannabis of CA$20million, up 8% quarter-over-quarter. The company posted positive adjusted EBITDA of CA$1 million and adjusted EBITDA from cannabis operations of CA$1.3 million in the quarter.
Cannabis stocks were a sea of red on Friday, weighed down by Green Organic Dutchman’s 14% decline after it said it would cut costs and adopt a plan to reduce its financing needs as it grapples with a smaller-than-expected Canadian market
Canadian cannabis producer Cronos Group is "a new king in the north," an analyst said in upgrading the stock.
The vaping crisis has brought on some twists and turns for the cannabis sector. New York courts are now weighing an e-cigarette ban.
Aurora Cannabis (ACB) is well-positioned for the inevitable rebound in the cannabis sector, as it ramps up production capacity, boosts its GMP-compliant output, and develops a variety of derivative products to serve the Canadian and international markets.By the end of June 2020, the company expects to have well over 625,000 kilograms in annual production capacity, and is now ready to increase the amount of GMP-compliant cannabis to send to the European market.In this article we're going to focus on the derivatives market in Canada, which while being approved of on October 17, 2019, won't be available for sale until December 17, 2019 because of the required 60-day review period required by Canadian law.With that in mind, the earliest glimpse investors will have concerning the potential impact on the performance of Aurora Cannabis and other marijuana companies based in Canada won't be until after the first calendar quarter of 2020; that's because it'll be the first full quarter derivatives will be sold in.Product categoriesThe three derivative categories Aurora is developing products for are vapes, concentrates, and edibles.In a press release the company said it "has prioritized its resources to prepare for a successful initial launch that will support an ongoing replenishment strategy to help ensure consumers across Canada will have access to a diverse portfolio of high-quality derivative products they want to buy."While I mentioned the first quarter will represent the first look at the potential for derivative sales, it needs to be understood that it won't reflect the full potential because the company is still developing products it'll introduce into the market after the initial launch. There will also be ongoing trial and error attempts to gain the most profitable product mix over time.VapesVapes are probably the most important category of the next stage of cannabis products because they're most in demand and command a price premium, although Aurora management did say it's going to offer a variety of vape products at different price points, targeting all the "major consumer markets."The major concern here is how much impact the vaping crisis will have on sales. While the vast majority of health issues and deaths have come from vape sales in the black market, it has cast a shadow on vaping in general.It's probable that this will be more visible and less of a concern by the time sales are launched in the latter half of December 2019.Edibles The initial offering in the edibles category will include baked goods, chocolates, gummies, and mints. How it works is "cannabis extract is infused throughout the product to provide consistency, texture and a great flavor."Concerning gummies and candies, the company said it has entered into two key partnerships with leading companies to devloped infused candies containing THC and CBD. Management claims it has positioned the company to be the market leader in Canada for edibles.It has also entered into a two-year global agreement to license JACEK Chocolate Couture's IP. JACEK is a luxury chocolate brand that Aurora will work with to develop cannabis-infused caramel filled chocolates and chocolate squares.On the baked goods side of the business, it has entered into a exclusive partnership with WG Pro-Manufacturing & Touché Bakery. Its Aurora River team will work with the two companies to develop this part of the derivatives market.At launch, one of the early products will be a vegan brownie cookie, followed rapidly by other unnamed products, according to Aurora.ConcentratesAll the products in the concentrates segment will be developed in-house. Among the product forms offered will be those including live rosin, shatter, and sugar wax.On the production side of the business, Aurora has build production facilities in key areas in various part of Canada, including Aurora River (Bradford, Ontario), Aurora Vie (Pointe Claire, Quebec) and at Aurora Sky (Leduc, Alberta).This will allow the company to not only distribute products in the Canadian market, but also in various international markets as well.$5.30 price targetIn a very upbeat report, Jefferies analyst Owen Bennett explained last week why he is reiterating a Buy rating on ACB stock. The analyst noted, "We don't think anyone can argue execution is impressive and on financials, although Aurora missed their target of being EBITDA positive in 4Q19, we do think they will move very close in next quarter, and will be positive into the 2nd half, supported by very impressive sales momentum (consumer feedback on brands is excellent). Another reason is likely near term positive newsflow catalysts, either/or both, an announcement around the US (they have committed to this over the coming quarters) and some kind of partnership with FMCG (remember they brought in Nelson Peltz as an advisor for this purpose)."Bennett has also suggested that if everything goes as planned, ACB will be a $5.30 stock in the next 12 months, implying well over 40% return. (To watch Bennett's track record, click here)ConclusionWhen analyzing Aurora Cannabis, there are three major things to consider: production capacity, GMP-compliance (for the EU market), and derivatives. All three of these are coming to fruition near the same period of time.The company will have more than enough supply to serve all the available markets that are rapidly emerging, as it develops a wide range of products in a variety of forms.Barring any unforeseen positive catalyst, Aurora will probably have its share price remain subdued through the end of 2019. But as the market takes into account the increase in revenue and widening margins associated with derivatives and its growing sales in Europe, it'll start rewarding the company once again as its production capacity climbs to over 625,000 kilograms per year by the end of June 2020, and probably closer to 700,000 kilograms per year.All this will be happening as Canada finally starts to roll out a lot more retail outlets for consumers to buy from. This will not only boost sales in general, but win more share from the black market.For these reasons I remain bullish on Aurora Cannabis, and consider it undervalued at this time.To find more good ideas for cannabis stocks trading at fair value or better, visit TipRanks’ Best Stocks to Buy, a newly launched feature that unites all of TipRanks’ equity insights.Disclosure: No position
Tilray (NASDAQ:TLRY), like other cannabis equities, continues to suffer from the effects of the bursting stock bubble. Tilray stock traded as high as $300 per share during the run-up in marijuana stocks, which preceded Canadian legalization in 2018. Since then, it has lost more than 92% of its value. This includes a nearly 35% drop in less than a week following its August earnings report.Source: Shutterstock To be sure, declines have hammered marijuana stocks across the board. Also, once the dust settles, the company holds key assets and partnerships that could eventually take TLRY stock higher.However, Tilray stock needs both changing sentiment and a more discernible path to stability before it can stem its decline.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Sector Selloff Hits TLRY StockTLRY trades at just over $22 per share. Despite this massive drop, TLRY stock still appears overvalued. Currently, it trades at about 24.3 times sales.In fairness, cannabis stocks have dropped across the board. Both Canopy Growth (NYSE:CGC) and Aurora Cannabis (NYSE:ACB) trade near 52-week lows. Moreover, companies such as Aphria (NYSE:APHA), which just beat earnings by 10 cents CAD per share, have also struggled. Many blame both changing sentiment against marijuana stocks as well as an oversupply of dried cannabis. * 7 Reasons to Buy Canopy Growth Stock In short, stocks that could do no wrong 18 months ago can now do no right. This bodes poorly for Tilray stock. InvestorPlace's Mark Hake even floated the possibility that TLRY could go bankrupt. Investors cannot write off that possibility as its reserves dwindle.TLRY holds about $180 million in cash. Since it lost $35 million in the last quarter, it can only maintain its current pace for so long. Moreover, Tilray cannot assume further debt will be an option. As of the previous quarterly report, the company held $430 million in long-term debt and $360 million in total equity. Hence, the financials indicate that the company may have to dilute its already beleaguered stock further when it comes time to seek more funding. TLRY Could Recover -- EventuallyDespite a bleak outlook and a lack of profits, investors still have reasons to keep watching Tilray stock. Much like the positive sentiment surrounding marijuana stocks did not last, investors should not assume the negative outlook will remain forever. When attitudes change, Wall Street may again pay attention to Tilray's attributes. Analysts forecast a 313.9% increase in revenue for this year. They also believe revenues will rise an additional 85.5% in fiscal 2020.Moreover, its partnerships and assets could eventually help TLRY. The company has partnered with a subsidiary of Novartis (NYSE:NVS) to distribute and sell branded medical cannabis products. It also entered into a joint venture with Anheuser-Busch InBev (NYSE:BUD) to research THC and CBD-infused beverages. Tilray also owns Manitoba Harvest, the world's largest hemp food manufacturer.This bodes well for continuing revenue growth. However, getting to the point where rising revenues can finally yield profits will probably lead to actions that place more strain on both the balance sheet and TLRY. Until the company can get to a place where it stops diluting Tilray stock, investors have little reason to buy. My Final Thoughts on Tilray StockTilray stock will struggle to move higher without improving its financials and without a more positive outlook from Wall Street on the cannabis sector. The bubble in TLRY continues to pop. The stock still appears pricey despite trading more than 90% below its all-time high. Sentiment has turned against marijuana stocks as losses continue and the industry contends with a glut in dried cannabis.Despite these obstacles, an eventual bullish scenario could develop for Tilray stock. It has built partnerships with established players in other industries. This could bode well for the Nanaimo, British Columbia-based firm as medicinal marijuana and cannabis-infused beverages find a market.However, for now, TLRY stock faces challenges as losses mount and liquid assets dwindle. Options for more funding will probably strain both the balance sheet and Tilray stock itself. For this reason, investors should probably brace for further near-term declines.As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You can follow Will on Twitter at @HealyWriting. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Reasons to Buy Canopy Growth Stock * 7 Restaurant Stocks to Leave on Your Plate * 4 Turnaround Plays to Buy Now The post Investors Beware: Tilray Stock Might Not Be Done Dropping appeared first on InvestorPlace.
It's been a hard year for marijuana firms and their investors. The industry has been wracked with worries about health concerns, waning demand and regulatory tie-ups. Naturally, this has taken a toll on marijuana stock prices.Aurora Cannabis (NYSE:ACB) is a prime example of a pot stock that's been hammered over the past 12 months. ACB stock has fallen 67% from where it was a year ago and many are speculating that the industry hasn't bottomed yet.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Troubled IndustryOne of the big reasons the industry is struggling right now is the slow-moving legalization process in Canada. The government is struggling to get through a backlog of licensing requests. That means companies that want to operate within Canada's legal marijuana market sometimes have to wait over a year for a permit.Canada's so-called "Cannabis 2.0" is slated to begin on October 17. During that time, the nation will legalize vaping products, edibles and cannabis-infused beverages. On the surface, that looks like a near-term catalyst for ACB. But if the nation's last round of marijuana legalization is anything to go by, we might be waiting a long time to see the benefits. * The 7 Best Penny Stocks to Buy On top of that, the marijuana industry is bumping up against health concerns as well. Vaping has been linked to 33 deaths across the U.S. and thousands of "lung injury cases." What's worse is that the Centers for Disease Control and Prevention says the majority of those patients have a history of using products that contain THC, the psychoactive chemical found in marijuana. Issues Involving ACB StockOf course, the industry-wide issues with obtaining legal permits put all marijuana firms on a level playing field. However, the vaping concerns weigh heavily on ACB stock as the firm is making big bets on the future of that industry. Management has consistently pointed to vaping as an area of focus. So, if regulators clamp down to avoid health problems, it could have a negative impact on Aurora stock.There are many out there, though, who look at the vaping issues as little more than a blip on the radar. After all, cigarettes contribute heavily to a host of terminal illnesses, but that market is still open for business. That's true, but the vaping concerns aren't the only problems Aurora stock is facing.Aside from its vaping bets, investors purchasing ACB stock are taking on some risky financials as well.The firm is in need of cash to continue funding its growth plans and likely has nowhere to turn aside from capital markets. Next March, ACB will have 230 million CAD worth of convertible debt to pay off. If the firm's share price is still in the gutter, it's doubtful the lenders will be willing to take the stock-conversion option. That means Aurora will likely take on even more debt, a worrying prospect for shareholders. The Silver Lining for Aurora StockOverall, Aurora Cannabis stock looks like a pretty shaky investment. It's uncertain financials and decision to focus on vaping makes it a risky bet. However, the firm does have some things going for itself.Aurora's sales make it the largest player in Canada and margins have been improving as costs fall. Plus, the firm has finally outlined plans to enter the CBD market, which is poised to explode in the coming years.ACB has aligned itself with Ultimate Fighting Championship in order to test whether CBD is effective in treating pain. The results of the study will eventually help Aurora develop a line of topical CBD products aimed at athletes. Potential PartnershipAnother potential positive for ACB stock is the fact that the firm is making its way as a leader in the cannabis industry without the help (or control) of a larger partner from another industry. The firm's rivals Canopy Growth (NYSE:CGC) and Cronos Group (NASDAQ:CRON) have inked deals with Constellation Brands (NYSE:STZ) and Altria (NYSE:MO), respectively.Aurora, on the other hand, is still flying solo. If everything pans out, that would be an advantage for long-term ACB stockholders as both Cronos and Canopy are likely to be bought out by their partners before they realize their full potential.Not everyone believes going it alone is the best option. Larger partners mean deeper pockets and better funding, which is something Aurora Cannabis stock could use right now. Also, the cross-industry tie is likely to help as marijuana products bleed into other consumer product lines in the future.There's also some question as to why big names aren't aggressively pursuing Aurora. The firm brought on infamous strategic advisor Nelson Peltz in what many believed was an effort to secure a cross-industry partnership. The Bottom LineACB stock doesn't look like it's heading to zero, but it might get close. Moreover, 20 years from now the stock might be a winner, but for now I'd remain on the sidelines.If you've got time and you're a sucker for a large risk/reward payoff, Aurora stock could be a winner. However, for now I think your capital is better deployed until there's a clearer picture of the firm's future on the table.As of this writing, Laura Hoy did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 7 Best Penny Stocks to Buy * 7 Bank Stocks to Avoid Now at All Costs * The 10 Best Mutual Funds for Your 401k The post This Isnat the Time to Buy Aurora Cannabis Stock appeared first on InvestorPlace.
The Cannabis 2.0 era has officially started. Now, Canadians can legally access a host of cannabis-infused products like beverages, vapes, and edibles.
Despite vaping concerns, Aurora Cannabis plans to introduce vape products in December. Reports of vaping-related illnesses started in late August.
With almost another month more to go before its next quarterly earnings report, Canopy Growth (NYSE:CGC) may keep trading at new lows. The company no longer has the benefit of speculators bidding blindly for cannabis stocks. Its last quarterly earnings report, posted on Aug. 14, missed analyst consensus estimates on earnings and revenue. Should investors take the risk of betting on the euphoria for cannabis stocks to come back? Or might investors want to sit out from holding CGC stock until the company proves its buildout will translate to profits?Source: Shutterstock Before speculating on a Canopy stock price rebound, investors must first understand why the company is exciting. Canopy is a multi-billion dollar company by market capitalization -- and it is building a business for the next several years. CGC operates in many countries and has 5 million square feet of capacity, plus licensed capacity. Added together, Canopy is ready to supply the market to meet demand. But the near-term challenge is hurting investor confidence not just in CGC stock, but in the sector.In Canada, Canopy is unable to meet demand due to limited storefronts. Another problem is falling prices. Add the CDC's warnings for e-cigarette risks and suddenly Canopy's reliance on so-called Cannabis 2.0 for growth is uncertain.InvestorPlace - Stock Market News, Stock Advice & Trading TipsCanopy's new CFO said that its near-term priorities include focusing on making sure the company is positioned for Cannabis 2.0. Vape products, CBD beverages and edibles are a big catalyst for revenue growth. But as Americans continue to question the safety of vaping, investors are right in selling CGC stock. The market is lowering the company's market cap and valuation to price in further risks ahead. Beverages and edibles may not get government approvals fast enough. Health agencies may take more time investigating the safety of derivative products. Canopy Growth's GoalsCanopy set a $1 billion revenue rate but is still short of that target. In the fiscal first quarter, net revenue was $90.5 million CAD. Its adjusted EBITDA of negative $92 million CAD also shook investor confidence. But to get to that set revenue rate, the company needs to invest in enterprise resource planning software to handle its global expansion ambitions. Clearly, back-end operations may take more time before it is ready. * The 7 Best Penny Stocks to Buy Stagnating growth is also a near-term headwind for Canopy stock, as the August report indicated. With growth falling behind its peers, the company is losing its competitive edge, pressuring investors to look elsewhere. Still, Aurora Cannabis (NYSE:ACB) and Cronos Group (NASDAQ:CRON) are both underperforming. Pressure on Gross MarginsCanopy started retrofitting its facility rooms last year in September. Its facilities were not harvesting as much as the company wanted. This disrupted output for the last few quarters and led to the company missing expectations. But once the overhead work is completed, the negative impact on gross margins will ease.In the last three quarters, Canopy's gross margins came in at 15%-22%. Once the retrofitting activities are completed, expect the levels to return to the high 40% range once again. With Cannabis 2.0, the company forecasts a 200-300 basis point productivity increase. This should add meaningfully to margins.Conservative investors should keep their eye on the existing business. Canada had around 460 stores and should get to 600 by the end of the year. If the industry, which includes Canopy, is able to supply to retail channels, Canopy should start seeing revenue acceleration. It will probably still report losses as the company faces startup costs for Cannabis 2.0. My Takeaway on CGCCanopy is a growth hope story that markets are unwilling to speculate on at this time. But the stock has hopeful investors who are not selling yet. The growth thesis is achievable but will take a few years to play out. The sector still also needs cannabis legalization to happen not only in Canada but in other major markets. If that happens, then the sector could pay off for investors buying CGC stock.As of this writing, Chris Lau did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 7 Best Penny Stocks to Buy * 7 Bank Stocks to Avoid Now at All Costs * The 10 Best Mutual Funds for Your 401k The post Where Is the Rebound for Fallen Canopy Growth Stock? appeared first on InvestorPlace.
Last October, Aurora Cannabis (NYSE:ACB) went public on the New York Stock Exchange. At the time, investors were full of optimism about the Canadian pot stock. The company beat out its rivals in terms of production capacity and was already expanding globally.But nearly a year later, ACB stock's prospects don't seem quite as strong. The company lost $6.8 billion in market cap as the stock has fallen steeply from its 52-week high of $12.53 per share. And Wall Street is deeply divided when it comes to the company. In general, most analysts are incredibly bullish or bearish when it comes to Aurora Cannabis stock, with very little in between. Out of the 15 analysts that are currently reviewing the stock, six consider it a buy, six recommend holding the stock, and three recommend selling.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * The 7 Best Penny Stocks to Buy Of course, the cannabis industry is expected to be huge in the coming years. But it's hard to disagree with the fact that Aurora's first year as a publicly-traded company has been a bit of a disaster. Listed below are three things you should know about ACB stock going forward. ACB's Balance Sheet Has Taken a HitOne of the things that made ACB stock so appealing in the first place is also the company's biggest downfall. Aurora Cannabis came out of the gate swinging and quickly blossomed into a global cannabis company. The company offers a diverse range of products, yet a bigger investor hasn't acquired it. The company's balance sheet has taken a significant hit as a result. Aurora has acquired over nine companies and in the process built up CA$3.17 billion in goodwill. Goodwill refers to the premium paid beyond the company's tangible assets during an acquisition. Canadian Retail Licenses Hit Major SnagThis problem affects all Canadian cannabis companies, including ACB stock. Health Canada is in charge of approving the cultivation and sales licenses for Cannabis companies. And the approval process has been taking longer than anyone expected it would. The agency is sitting on an enormous backlog of licensing applications, meaning cannabis companies are sitting on products that they are unable to sell. And individual provinces have been struggling with their own licensing approval issues. Wall Street Quickly Souring on ACB StockOver the past month, Aurora Cannabis has received three sell ratings. And one of these ratings came from Stifel analyst Andrew Carter. Carter lowered the company's price target and lowered its rating, citing the company's domestic and global weakness as the reason why. MKM Partners also gave the company a sell rating, saying the company needs to raise more capital before it can hope to become profitable.Analyst ratings aren't always accurate or the best indication of whether you should buy a stock. But these ratings encapsulate the general wariness many people have toward the company. Aurora stock is going to have a lot of ground to make up to prove it can reach profitability. As of this writing, Jamie Johnson did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 7 Best Penny Stocks to Buy * 7 Bank Stocks to Avoid Now at All Costs * The 10 Best Mutual Funds for Your 401k The post One Year After Going Public, Is the Growth Story Over for ACB Stock? appeared first on InvestorPlace.
On Wednesday, Aurora Cannabis gave a preview of its Cannabis 2.0 strategy. The company provided plans for the roll-out of edibles, concentrates, and vapes.
Respecting the first anniversary of cannabis legalization in Canada, Aurora Cannabis (NYSE: ACB) (TSX: ACB) announced Wednesday its plans to roll out cannabis products that will be authorized for sale in December. The company’s new products will include vapes, concentrates and edibles will be sold to consumers across Canada. "Aurora's product development and Insight teams have done tremendous work to formulate new products in a variety of formats that we think will exceed consumer expectations and drive category growth," CEO Terry Booth said in a statement.